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Abstract
Changes of membrane lipids in cisplatin-sensitive A549 and cisplatin-resistant A549/DDP cells
during the apoptotic process induced by a clinical dose of cisplatin (30 µM) were detected by 1H
and 31P-NMR spectroscopy and by membrane fluidity measurement. The apoptotic phenotypes of
the two cell lines were monitored with flow cytometry. The assays of apoptosis showed that
significant apoptotic characteristics of the A549 cells were induced when the cells were cultured
for 24 hours after treatment with cisplatin, while no apoptotic characteristic could be detected for
the resistant A549/DDP cells even after 48 hours. The results of 1H-NMR spectroscopy
demonstrated that the CH2/CH3 and Glu/Ct ratios of the membrane of A549 cells increased
significantly, but those in A549/DDP cell membranes decreased. In addition, the Chol/CH3 and Eth/
Ct ratios decreased for the former but increased for the latter cells under the same conditions.
31P-NMR spectroscopy indicated levels of phosphomonoesters (PME) and ATP decreased in A549
but increased in A549/DDP cells after being treated with cisplatin. These results were supported
with the data obtained from 1H-NMR measurements. The results clearly indicated that
components and properties of membrane phospholipids of the two cell lines were significantly
different during the apoptotic process when they were treated with a clinical dose of cisplatin.
Plasma membrane fluidity changes during cisplatin treatment as detected with the fluorescence
probe TMA-DPH also indicate marked difference between the two cell lines. We provided
evidence that there are significant differences in plasma membrane changes during treatment of
cisplatin sensitive A549 and resistant A549/DDP cells.
Background
Chemotherapy can cure many human cancers, but drug
resistance – intrinsic or acquired – is a major problem for
many patients. Many changes are associated with multi-
drug resistance (MDR) of tumor cells [1,2]. One of them,
alterations of drug accumulation and distribution in cells
seem to play an important role in MDR [3]. Efflux pumps,
such as, P-glycoprotein, MRP (multi-drug resistance pro-
tein), and LRP (lung resistant protein) can decrease drug
accumulation in cells and make chemotherapy ineffective
[4]. The plasma membrane plays an important role in the
control of intracellular concentration, efflux and influx of
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drugs. Many anticancer drugs show membrane effects via
weak hydrophobic interaction or via electrostatic binding
to membrane phospholipids before entering the cyto-
plasm. Adriamycin, for example, interacts with the mem-
brane by increasing the turnover of phosphatidylinositol
[5], and cisplatin can interact with phosphatidylserine to
alter the characteristic of the membrane [6]. Remarkably,
in tumor cells, the development of drug resistance usually
has been associated with changes in their plasma mem-
brane phospholipids. For example, daunomycin-resist-
ance in P338 cells [7] is associated with fewer drugs
retained in resistant cells than in their sensitive counter-
parts and the resistant cells were shown to have a lower
phosphatidylserine content and a higher cholesterol con-
tent in their plasma membrane than sensitive cells. The
development of vinblastine resistance in human leukemic
lymphoblast was associated with an increase in cholester-
ol and phopholipids content in their membranes [8]. In
Ehrlich ascites tumor cells, resistance was reported to de-
pend on the level of phospholipids in the plasma mem-
brane [9]. These observations demonstrate the
relationship between drug resistant phenotypes and the
changes of the components and properties of the plasma
membrane lipids.
Fluorescence measurement is a method used to detect the
physical state changes of membrane lipids. Recently, 1H-
NMR and 31P-NMR spectra have also been used in detect-
ing changes of membrane lipids. NMR provides a rapid,
accurate, and noninvasive means particularly useful for
detection of changes in membrane lipids in living cells
[10]. Physical state differences between human lung ade-
nocarcinoma cisplatin sensitive A549 and cisplatin resist-
ant A549/DDP cells were reported previously by
fluorescence measurement in our laboratory [11]. Pres-
ently, we have extended this study, by following the apop-
tosis process and plasma membrane fatty composition of
the cisplatin sensitive A549 and resistant A549/DDP cells
after treatment with a clinical dose of cisplatin.
Results
Apoptotic characteristics of A549/DDP cells
Recently, flow cytometry has been applied to study DNA
changes of cellular population [12] in order to detect cell
apoptotic characteristics. Fig. 1 shows the apoptotic peak
of the two cell lines monitored by flow cytometry. It can
be seen that the sub-G1 phase of the sensitive A549 cells
appeared after 24 h culture of the cells [Fig. 1(b)], but
there is no sub-G1 phase of the resistant A549/DDP cells
even after 48 h culture [Fig. 1(f)]. Apoptotic cells of the
sensitive A549 increased from 55% at 24 h to 72% at 48 h
compared to the control in sensitive A549 cells [Fig. 1(a)].
The 1H-NMR spectra of sensitive A549 and resistant A549/
DDP cells
The 1D 1H-NMR spectra of A549 and A549/DDP cells are
showed in Fig. 2(A) and Fig. 2(B), respectively. Table 1
lists the ratios of the corresponding peak intensities. The
changes in composition and properties of the membrane
lipids between the two cell lines can be deduced from
changes of the peak intensities of fatty acids [13]. It can be
seen that there is an increase in CH2/CH3 and Glu/Ct ra-
tios but a decrease in Chol/CH3 and Eth/Ct ratios of the
A549 cells during the apoptotic progress induced by cispl-
atin. However, it is noticeable that the changes of CH2/
CH3 and Glu/Ct ratios as well as Chol/CH3 and Eth/Ct ra-
tios of the resistant A549/DDP cells are just the opposite
from those of the sensitive A549 cells.
The 31P-NMR spectra of sensitive A549 and resistant A549/
DDP cells
Typical 31P-NMR spectra of A549 and A549/DDP cells ob-
tained at 22°C are shown in Fig. 3(A) and 3(B), respec-
tively. The resonance at 18 ppm is from 10 mM
methylene-diphosphonate used as external concentration
standard. Prominent peaks are observed for phosphomo-
noesters (PME), primarily from phosphoryl-eth-
anolamine (PE) and phosphorylcholine (PC); Pi, α-ATP;
β-ATP;  γ-ATP; and nicotinamide adenine dinucleotide
(NAD), as well as uridine diphosphoglucose (UDPG)
[14]. The signal corresponding to β-ATP was used for
quantitation of all ATP resonances since there is no over-
lap of β-ATP resonance with other 31P signals. Changes of
phosphorus metabolites of the two cell lines were shown
in Table 2. 31P-NMR spectra indicated that the levels of
PME and ATP were reduced in A549 but enhanced slightly
in A549/DDP after treatment with cisplatin.
The microviscosity of the plasma membrane of the resist-
ant A549/DDP cells increased
A fluorescence probe TMA-DPH, which is a derivative of
DPH, was used to detect the change of microviscosity of
the living cells. This dye localized specifically in the plas-
ma membrane for a sufficient time to allow plasma mem-
brane fluidity and heterogeneity measurements of the
whole cells [15]. The changes of microviscosity of the
plasma membrane of A549 and A549/DDP cells are
showed in Fig. 4. It is clear that microviscosity of the plas-
ma membrane of the sensitive A549 cells induced by cis-
platin decreased but that of the resistant A549/DDP
treated the same increased.
Conclusion
The apoptotic characteristics of tumor cells play an impor-
tant role in the development of cancer, studies on changes
of plasma membrane phospholipids during the process of
apoptosis of MDR tumor cells treated with chemothera-
peutic drugs may indicate molecular mechanisms of theCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/5
Page 3 of 8
(page number not for citation purposes)
Figure 1
Flow cytometry histograms of A549 and A549/DDP cells treated with a clinical dose of 30 µM cisplatin. a, b, c stands for A549 
cells treated and cultured for 0, 24, and 48 h, respectively, and d, e, f for A549/DDP cells under the same conditions.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/5
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MDR phenomena. NMR spectroscopy can provide an as-
sessment of lipid composition and changes in membrane
fluidity in relation to drug resistance and apoptosis.
Mountford [16] reported that, 1H-NMR spectroscopy can
provide information on phospholipids in cellular mem-
branes. Different groups in phospholipid molecules are
located in microenvironments in membranes that are
physical-chemically heterogeneous, and can be surveyed
in 1H-NMR spectra as chemical shifts (ppm). Singh JK et
al. [17] observed a significant increase in the proportion
of saturated fatty acid side chains in phosphatidylserine
(PS) and phosphatidylinositol when apoptosis was trig-
gered in a clonal neuronal (hippocampal) cell line (HN2-
5) by hypoxia or nutrient deprivation. Dynamic proper-
ties of plasma membrane are affected if the composition
and characteristics of the phospholipids contained in the
plasma membrane change. Our data clearly indicated that
the peak ratios of CH2/CH3 and Glu/Ct for the sensitive
A549 cells [Fig. 2(A)] increased 1.3- and 1.5-fold, respec-
tively, compared to the resistant A549/DDP cells [Fig.
2(B)], furthermore these changes were further increased
for the former during the apoptotic process induced by
cisplatin, but decreased for the resistant A549/DDP (Table
1). Also, changes of the peak ratios of Chol/CH3 and Eth/
Ct for the sensitive A549 cells were just the opposite from
those of the resistant 549/DDP cells. These differences im-
plied that changes in the composition of the membrane
phospholipids in the two cell lines may be responsible for
inducing changes of membrane dynamic characteristics,
such as microviscosity or fluidity. Mountford reported
that, in tumor cells, the decrease in microviscosity of the
plasma membrane was related to the increase in CH2/
CH3 ratio detected by 1H-NMR spectroscopy [18,19]. Our
results obtained by 1H-NMR measurement are further
supported by the measurement with the fluorescence dye
TMA-DPH [Fig. 4].
It seems there are no experiment to support, it was sug-
gested before, based on 31P-NMR studies that phospholi-
pid metabolism is characteristic for tumor cells [20]; Liora
[21] et al. demonstrated that there was a decrease in phos-
phatidylcholine level in human breast cancer cells during
apoptosis due to the inhibited choline transport and the
enhanced activity of phosphocholine: cytidine triphos-
phate cytidylyl-transferase. We speculate that the decrease
of the Chol/CH3 ratio in A549 cells and the increase of the
Chol/CH3 ratio in A549/DDP cells reflect biosythesis dif-
ferences of phosphatidylcholine and/or the phospho-
choline:cytidine triphosphate cytidylyl-transferase
between A549 and A549/DDP cells. These differences
may also be related to the different apoptotic characteris-
tics of the two cell lines.
31P-NMR measurements were carried out for gaining an
additional insight into the changes of phosphorus metab-
olism in the two cell lines after cisplatin treatment. A high-
er PME (PE and PC) and ATP levels were found in A549
cells in comparison with those of A549/DDP cells [Fig.
3(A), 3(B), Table 2]. A higher level of PME in some cells
was considered to correlate with a higher rate of cell pro-
liferation [22]. This may be one reason why A549 cells
Figure 2
1H-NMR spectra of A549 cells (A) and A549/DDP cells (B) 
treated with a clinical dose of 30 µM cisplatin and cultured 
for 0 h, 24 h, and 48 h. The cell concentrations are compara-
ble (1 × 107 cells/mL) for each sample. The peak assignments 
are shown in the figures. Number of scans was 128.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/5
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grow faster than A549/DDP cells. But after treatment with
cisplatin, the level of PME decreased gradually in A549
but increased in A549/DDP. These results were consistent
with the data obtained from 1H-NMR measurements
above. In addition, the pronounced broader peak of PME
of A549 cells than that of A549/DDP indicates that the
head groups of the phospholipid (PE and PC) in A549
cells move slower than those of A549/DDP cells. The in-
crease and decrease in the level of ATP in A549/DDP and
A549 cells, respectively, were manifested under the same
condition. The increase of PME and ATP in A549/DDP
cells responding to the treatment with cisplatin would be
a molecular mechanism involved in their cisplatin-resist-
ant phenotype.
In addition to lipid signal modification, 1H-NMR spec-
troscopy demonstrated that the other possible metabo-
lites were affected along with apoptosis, such as the
glutamine and inositol content. Glutamine, glutamate
and glutathione (GSH) are used by the cells for detoxifica-
tion via glutathione conjugation. GSH covalently binding
cisplatin at physiological concentration [23–25] and di-
rect reaction between GSH and cisplatin in cells had been
reported [26]. Though depletion of GSH by buthionine
sulphoximine (BSO) have been ever reported not to en-
hance cisplatin sensitivity in some cell lines [27,28], there
is considerable evidence linking GSH to cisplatin resist-
ance [29–31] and depletion of GSH by buthionine sul-
phoximine (BSO) enhanced authentically cisplatin
sensitivity in some cell lines [31,32]. Our data indicated
that the decrease of Glu in A549/DDP [Fig. 2(A) and
2(B)], and Table (1) might be due to a higher turnover of
these metabolites in the resistant cells A549/DDP in the
metabolic pathway of glutamine to glutamate to glutath-
ione, to increase glutathione conjugation. Our results are
in good agreement with previous reports indicating in-
creased glutathion-S transferate activity in resistant cells
[33].
In summary, all the NMR and fluorescence anisotropy
studies indicated that distinct differences of phospholipid
components and properties of the plasma membrane are
between sensitive A549 and resistant A549/DDP cells in
the apoptotic process induced with a clinical dose of cis-
platin (30 µM). We suggest that these differences play sig-
nificant role in the cisplatin resistant phenotype of the
A549/DDP cells.
Materials and Methods
Reagents
Cisplatin, penicillin, streptomycin, trypsin, methylene di-
phosphonate, percoll and 2, 2-Dimethyl-2-silapentane-5-
sulfonic acid (DDS) were purchased from Sigma, and 6-
diphenyl-1, 3, 5-hexatrine (TMA-DPH) and propidium io-
dide (PI) from Molecular Probes. Deuterium oxide was
from Cambridge Isotope Laboratories, Inc. (Andover, MA,
USA). Other reagents were local products of analytic
grade.
Cell lines and cell culture
The parental cell line A549, a human adenocarcinoma cell
line, and the cell line A549/DDP, which is resistant to cis-
platin (CDDP or DDP), were generously provided by Bei-
jing Cancer Institute, (Beijing, China.) The cell culture
conditions were described previously [11]. Cells used for
the experiments were in the logarithmic phase of growth.
Apoptosis induced by cisplatin and measured by flow 
cytometry
Cells were treated with a clinical dose (30 µM) of cisplatin
for 4 h, and were further cultured in cisplatin-free medi-
um for different time periods. The treated cells were
rinsed, trypsinized, pelleted and resuspended in cold PBS
at the desired time. To assay the apoptosis, the cells were
fixed dropwise with ice-cold 100% ethanol to yield a final
concentration of 70%. The suspended cells were stored at
4°C overnight, and then washed three times with PBS to
remove the ethanol. The DNA of the cells was labeled by
propidium iodide as described previously [12]. The cell
Table 1: Peak intensity ratios of 1H NMR spectra obtained from A549 and A549/DDP cells treated with 30 µM cisplatin and cultured for 
0 h, 24 h, and 48 h.
Cells Treated time CH2/CH3 Chol/CH3 Glu/Ct Eth/Ct Ino/Ct
A549 0 hrs 3.63 ± 0.08 0.26 ± 0.06 4.11 ± 0.15 0.56 ± 0.05 0.23 ± 0.07
24 hrs 4.12 ± 0.09 0.19 ± 0.05 4.39 ± 0.18 0.41 ± 0.06 0.16 ± 0.06
48 hrs 4.25 ± 0.06 0.11 ± 0.06 4.94 ± 0.12 0.33 ± 0.05 0.12 ± 0.08
A549/DDP 0 hrs 2.21 ± 0.09 0.28 ± 0.06 3.66 ± 0.27 0.68 ± 0.04 0.25 ± 0.04
24 hrs 2.04 ± 0.06 0.33 ± 0.04 3.62 ± 0.16 0.74 ± 0.06 0.29 ± 0.08
48 hrs 1.66 ± 0.08 0.39 ± 0.09 3.60 ± 0.03 0.86 ± 0.05 0.33 ± 0.06
Data represent mean values ± SD (n = 3). P < 0.05.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/5
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cycle and the apoptotic peak were analyzed using Becton-
Dickinson FACS-420 flow cytometry equipped with 2 W
argon laser and tuned to 488 nm excitation and 525 nm
emission wavelength.
1H-NMR measurements
The cells for 1H-NMR samples cultured as described above
were harvested and resuspended in cold 1 × PBS. After-
wards, the cells were washed twice with PBS and subse-
quently with PBS-D2O to diminish NMR signal
interference by H2O. The single cells were resuspended in
PBS-D2O (1 × 107 cells/mL) for 1H-NMR experiments. All
the  1H-NMR data were collected on Bruker Avance
DMX600 spectrometer. Samples were spun at the speed of
17 Hz to avoid cell sedimentation during data collection
at 37°C. 128 scans were recorded for each FID. The inter-
ference from residual water was eliminated using the WA-
TERGATE technique [34]. The chemical shifts of the
resonance groups were referenced to internal standard
DDS (2,2-Dimethyl-2-silapentane-5-sulfonic acid 20 µM)
at 0 ppm. Data processing and integration of the peak area
of the resonances were performed with Felix 98.0 soft-
ware. The resonances of chemical groups monitored by
1H-NMR were as following [13]: Methyl (CH3) resonanc-
es from fatty acids integrated between 0.75 and 1.10 ppm;
menthylene (CH2) resonances from fatty acids between
1.15 and 1.5 ppm; Glu between 2.5 and 1.8 ppm; Ct be-
tween 2.9 and 3.1 ppm; N-trimethyl of Chol between 3.3
and 3.1 ppm; Ino between 3.6 and 3.5 ppm; and Eth be-
tween 3.8 and 3.7 ppm. The lipid resonance areas were
reported as the ratios to CH3, and the metabolite areas as
the ratios to Ct [13].
31P-NMR measurements
31P-NMR spectra of the intact cells were obtained on a
Bruker Avance DPX400 spectrometer operating at
161.943 MHz phosphorus frequencies at 22°C. For each
31P-NMR experiment, the treated cells (5 × 108 cells/mL)
were rinsed, trypsinized, pelleted and resuspended in cold
isotonic mixture of RPMI 1640, supplemented by 40 mM
glucose, 20 mM HEPES (pH 7.4) to provide sufficient sus-
tenance and buffering capacity, and 40% (V/V) percoll to
prevent cells sedimentation during 31P-NMR experi-
ments. 0.6 mL cell suspension was transferred to a 5 mm
NMR tube, which was then quickly placed in the magnet.
The data were recorded with a spectral width of 50 ppm
and 8 K data point, 2000 scans were collected for each
FID. The 31P signals were referenced to an external stand-
ard of 85% phosphoric acid (2.3 ppm) and for the quan-
titative analysis; the peak areas were reported as the ratios
to methylene-diphosphonate [14].
Microviscosity of plasma membrane measured using TMA-
DPH
2 mM of stock solution of TMA-DPH dissolved in tetrahy-
drofuran was stored in the dark at 4°C. Cells suspended
in PBS (1 × 106cells/mL) were incubated in a final
Figure 3
31P-NMR spectra of A549 cells (A), A549/DDP cells (B) 
treated with a clinical dose of 30 µM cisplatin and cultured 
for 0 h, 24 h, and 48 h. The cell concentrations are compara-
ble (5 × 108 cells/mL) for each sample. The peak assignments 
are shown in the figures. 2000 transients were accumulated 
for each spectrum.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/5
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concentration of 2 µM TMA-DPH for 20 min at 37°C. Ex-
perimental methods were according to Pangdey et al. [35].
The fluorescence anisotropy, γ, was obtained from the re-
lation γ = 2P/(3-P) where P is polarization. The microvis-
cosity of the plasma membrane was calculated by the
Perrin equation γ0/γ = [1 + C(γ)·T·τ]/Η, where γ0 = limit-
ing fluorescence anisotropy (0.36 for DPH), C(γ) = A pa-
rameter relating to the molecular shape and location of
the transition dipoles of rotating fluorophore. T = abso-
lute temperature, τ = excited state life lime (for DPH 11.4
ns), Η = microviscosity of the medium. The variation of C
(γ) or τ for a system labeled with same probe and temper-
ature is considerable smaller than the variation of Η.
Therefore, the quantity (γ0/γ-1)-1 is taken as the apparent
microviscosity,  , of the medium. C (γ)·T·τ = 2.4 poise.
The apparent microviscosity ( ) = 2.4γ/(0.362-γ) poise.
Abbreviation
MDR, multidrug resistance; NMR, nuclear magnetic reso-
nance; Glu, glutamine-glutamate; Ct, creatine-creatinine;
Chol, choline and derivative compounds. Ino, inositol;
Eth, ethanolamine; TMA-DPH, 6-diphenyl-1, 3, 5-hex-
atrine; PME, phosphomonoesters; FID, free induction de-
cay; DDS, 2, 2-Dimethyl-2-silapentane-5-sulfonic acid.
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